Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Michael Chiarella
- Phone Number: 1-858-945-2415
- Email: mchiarella@xencor.com
Study Locations
-
-
-
Hasselt, Belgium, 3500
- Jessa Ziekenhuis - Campus Virga Jesse
-
-
-
-
-
Thessaloniki, Greece, 552 36
- St. Lukes (Agios Loucas) Hospital
-
-
-
-
-
Johor Bahru, Malaysia, 81100
- Hospital Sultan Ismail
-
Kuching, Malaysia, 93586
- Hospital Umum Sarawak
-
Putrajaya, Malaysia, 62250
- Institut Kanser Negara
-
-
-
-
North Holland
-
Amsterdam, North Holland, Netherlands, 1066 CX
- The Netherlands Cancer Institute - Antoni van Leeuwenhoek
-
-
-
-
-
Guimarães, Portugal, 4835-044
- ULS do Alto Ave, EPE - Hospital da Senhora da Oliveira Guimarães
-
-
-
-
-
Barcelona, Spain, 08036
- Hospital Clinic i Provincial de Barcelona
-
Barcelona, Spain, 08023
- NEXT Oncology-Hospital Quironsalud Barcelona
-
Girona, Spain, 17007
- Institut Català d'Oncolgia de Girona
-
Madrid, Spain, 28040
- Hospital Clinico San Carlos
-
Madrid, Spain, 28046
- Hospital Universitario La Paz
-
-
-
-
-
Changhua, Taiwan, 500
- Changhua Christian Hospital
-
Kaohsiung City, Taiwan, 807
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
-
-
-
Arizona
-
Glendale, Arizona, United States, 85304
- Palo Verde Cancer Specialists
-
-
Connecticut
-
Norwich, Connecticut, United States, 06360
- Eastern Connecticut Hematology and Oncology Associates
-
-
Virginia
-
Fredericksburg, Virginia, United States, 22408
- Hematology Associates of Fredericksburg
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Histologically confirmed, locally advanced (unresectable) or metastatic nonsquamous NSCLC
- Documented absence of tumor activating EGFR mutation, ALK gene and ROS1 rearrangements, and alterations in any actionable driver oncogenes for which there are locally approved targeted first-line therapies
- PD-L1 IHC testing documenting TPS < 49%
- No prior systemic treatment for advanced/metastatic NSCLC.
- Measurable disease by RECIST 1.1
- ECOG performance status score of 0 or 1
- Life expectancy ≥ 3 months
- Adequate liver, kidney, thyroid and bone marrow function
Key Exclusion Criteria:
- Have known active central nervous system metastases and/or carcinomatous meningitis. Patients with treated brain metastases may participate, provided they are radiologically stable
- Active known or suspected autoimmune disease
- Has any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug
- Interstitial lung disease that is symptomatic
- Known human immunodeficiency virus (HIV) positive with CD4+ T-cell (CD4+) count < 350 cells/μL, or an HIV viral load greater than 400 copies/mL, or a history of an acquired immunodeficiency syndrome-defining opportunistic infection within the past 12 months, or not on established antiretroviral therapy (ART) for at least 4 weeks prior to initiation of study drug dosing. (HIV positive subjects who do not meet these exclusion criteria are eligible)
- Positive test for hepatitis C RNA (a patient who is hepatitis C virus [HCV] antibody positive but HCV RNA negative due to documented, curative prior antiviral treatment or natural resolution is eligible)
- Positive test for hepatitis B surface antigen or hepatitis B core antibody (hBcAb) (a patient whose hBsAg is negative and hBcAb is positive may be enrolled if a hepatitis B virus (HBV) DNA test is negative and the subject is retested for HbsAg and HBV DNA every 2 months)
- History or evidence of any clinically unstable/uncontrolled disorder, condition, or disease (including, but not limited to, cardiopulmonary, renal, metabolic, hematologic, or psychiatric) other than NSCLC, that, in the opinion of the Investigator, would pose a risk to patient safety or interfere with study evaluations, procedures, or completion
Other protocol defined inclusion/exclusion criteria apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Vudalimab + Carboplatin + Pemetrexed
|
Vudalimab intravenous + carboplatin intravenous + pemetrexed intravenous
|
|
Active Comparator: Pembrolizumab + Carboplatin + Pemetrexed
|
Pembrolizumab intravenous + carboplatin intravenous + pemetrexed intravenous
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Part 1: Recommended Phase 2 dose of vudalimab in combination with chemotherapy
Time Frame: Day 1 to Day 21
|
Incidence of treatment-emergent adverse events and treatment-related adverse events leading to discontinuation of treatment
|
Day 1 to Day 21
|
|
Part 2: Progression free survival
Time Frame: Day 1 to 2.5 years
|
Progressive disease per RECIST 1.1 or death, whichever comes first
|
Day 1 to 2.5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Antitumor activity
Time Frame: Day 1 to 1.4 years
|
Objective response rate as determined by investigator, duration of response (Part 1 and Part 2)
|
Day 1 to 1.4 years
|
|
Changes in circulating tumor DNA (ctDNA)
Time Frame: Day 1 to 1.4 years
|
Examine ctDNA changes as a surrogate marker for disease burden (Part 1 and Part 2)
|
Day 1 to 1.4 years
|
|
Maximum Serum Drug Concentration (Cmax)
Time Frame: Day 1 to 1.4 years
|
(Part 1 and Part 2)
|
Day 1 to 1.4 years
|
|
Trough Serum Drug Concentration (Ctrough)
Time Frame: Day 1 to 1.4 years
|
(Part 1 and Part 2)
|
Day 1 to 1.4 years
|
|
Area Under the Concentration-time Curve (AUC)
Time Frame: Day 1 to 1.4 years
|
(Part 1 and Part 2)
|
Day 1 to 1.4 years
|
|
Overall survival
Time Frame: Day 1 to 2.5 years
|
Time to death from any cause (Part 2)
|
Day 1 to 2.5 years
|
|
Incidence of treatment-emergent adverse events
Time Frame: Time Frame: Day 1 to 1.4 years]
|
Time Frame: Day 1 to 1.4 years]
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Jolene Shorr, Executive Director, Clinical Development
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Respiratory Tract Diseases
- Lung Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Amino Acids, Peptides, and Proteins
- Organic Chemicals
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Coordination Complexes
- Guanine
- Hypoxanthines
- Purinones
- Purines
- Glutamates
- Amino Acids, Acidic
- Amino Acids
- Amino Acids, Dicarboxylic
- Pemetrexed
- Carboplatin
- pembrolizumab
Other Study ID Numbers
Other Study ID Numbers
- XmAb717-06
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.